Biotechs worldwide are partnering with CDMOs more than ever as therapies grow more sophisticated and manufacturing demands intensify. CDMOs offer end-to-end development, scalable systems, and regulatory support—capabilities many innovators cannot rapidly build internally. By leveraging CDMO expertise, biotechs can accelerate timelines, control costs, and ensure high-quality production... https://xellera.livejournal.com/4599.html